Trending...
- Liquidity Aggregation: US-Registered JHKXWL Integrates AI Analytics for Brazilian and Global Institutional Traders - 165
- Cyntexa Announces Updates to ChargeOn on Salesforce AppExchange
- ToneWell Launches AI Wellness Platform with 30-Second Voice-Based Performance Readiness Scan™
AVENTURA, Fla. - PennZone -- Dr. Jeff Gelblum, Neurologist at First Choice Neurology, has brought together clinical, imaging, and laboratory capabilities to provide rapid diagnosis and treatment to individuals suffering from Alzheimer's disease.
The patient journey of Alzheimer's evaluation and management involves a clinical assessment to determine the level of cognitive impairment, and imaging studies of the brain, MRI, and PET scans to identify the presence of brain amyloid plaques. Also included are laboratory capabilities to inform the tolerability of the new anti-Alzheimer medication, and an experienced infusion team capable of providing the new class of FDA-approved medication in a comfortable setting.
Dr. Gelblum's highly integrated program will eliminate the long delays and fragmented care that typically plague patients seeking Alzheimer's treatment.
He observes, "that the new class of disease-modifying treatments are only approved in mild Alzheimer's which offers only a short window of opportunity to treat. In the US and abroad, it can often take up to a year to get a neurology appointment, and by that point, the patient may have progressed to a point where they might no longer respond to treatment."
More on The PennZone
Dr. Gelblum's program eliminates the delay and provides a quick and comprehensive work-up in the Aventura medical district, just north of Miami, Florida.
Dr. Gelblum boasts that "within 48 hours we can diagnose and begin infusion therapy. This means that the patient can check in to our on-campus hotel on a Tuesday evening, undergo evaluation in our clinic Wednesday morning, receive diagnostic testing Wednesday and Thursday, and then obtain their infusion treatment on Friday."
For those patients who reside out of town, his infusion center can dispense medication to-go for follow-up infusion treatments in their hometown medical facility. This is ideal for out-of-town patients who may not have easy access to a neurologist. He can then follow the patient remotely via telehealth.
His Aventura clinic is easily accessible via Miami or Fort Lauderdale international airports.
Dr. Gelblum has a global patient population who has discovered the ease of access and convenience of care provided by this program. He has patients from the UK, Spain, France, Israel, Russia, South Korea, Central and South America, and the Caribbean. They are diagnosed in his Aventura clinic and then followed up remotely via Skype, WhatsApp, FaceTime, or any manner of live audiovisual interface.
More on The PennZone
Dr. Gelblum observes, "that in this day and age of disease-modifying therapy and instantaneous telecommunications, it is unacceptable for medically necessary neurological care and treatment to be delayed."
He looks forward to welcoming Alzheimer patients from all over to his Aventura, Florida clinic.
About Jeffrey Gelblum, MD, FAAN
Dr. Jeff Gelblum is a neurologist with First Choice Neurology located in Aventura, Florida. He is considered a global thought leader in the neurologic treatment of Alzheimer's, dementia, seizure disorders, Parkinson's, diabetic and peripheral nerve disorder, Familial Amyloid Polyneuropathy, Covid Long-Hauler, trauma, and chronic pain, and has hosted educational symposia in the U.S. and overseas. To learn more about Dr. Gelblum, visit https://www.fcneurology.net/business-directory/788/jeffrey-gelblum-md/
The patient journey of Alzheimer's evaluation and management involves a clinical assessment to determine the level of cognitive impairment, and imaging studies of the brain, MRI, and PET scans to identify the presence of brain amyloid plaques. Also included are laboratory capabilities to inform the tolerability of the new anti-Alzheimer medication, and an experienced infusion team capable of providing the new class of FDA-approved medication in a comfortable setting.
Dr. Gelblum's highly integrated program will eliminate the long delays and fragmented care that typically plague patients seeking Alzheimer's treatment.
He observes, "that the new class of disease-modifying treatments are only approved in mild Alzheimer's which offers only a short window of opportunity to treat. In the US and abroad, it can often take up to a year to get a neurology appointment, and by that point, the patient may have progressed to a point where they might no longer respond to treatment."
More on The PennZone
- Star Sleep & Wellness Expands to Pearland, Texas — Bringing Life-Changing Sleep Care to More Communities
- Fort Lauderdale Dentist Dr. Taskonak & IN A DAY SMILE Receive Emmy Nomination for Life-Changing Documentary "The Weight of a Smile"
- Men's Health Network Highlights Major 2025 Achievements & Launches New Donation Platform For Greater Impact
- BET and Soul Train Awards - GONE! - Introducing The World Hip Hop Awards
- Australian Aboriginal Cultural Immersions and First Nations Workshops
Dr. Gelblum's program eliminates the delay and provides a quick and comprehensive work-up in the Aventura medical district, just north of Miami, Florida.
Dr. Gelblum boasts that "within 48 hours we can diagnose and begin infusion therapy. This means that the patient can check in to our on-campus hotel on a Tuesday evening, undergo evaluation in our clinic Wednesday morning, receive diagnostic testing Wednesday and Thursday, and then obtain their infusion treatment on Friday."
For those patients who reside out of town, his infusion center can dispense medication to-go for follow-up infusion treatments in their hometown medical facility. This is ideal for out-of-town patients who may not have easy access to a neurologist. He can then follow the patient remotely via telehealth.
His Aventura clinic is easily accessible via Miami or Fort Lauderdale international airports.
Dr. Gelblum has a global patient population who has discovered the ease of access and convenience of care provided by this program. He has patients from the UK, Spain, France, Israel, Russia, South Korea, Central and South America, and the Caribbean. They are diagnosed in his Aventura clinic and then followed up remotely via Skype, WhatsApp, FaceTime, or any manner of live audiovisual interface.
More on The PennZone
- Uk Financial Ltd Featured In New York Business Now — 2019 Gold-Backed Bitcoin Prediction Now Becomes SEC Security Token Filing
- MROVI Trailer Parts Launches Its Own Tire Brand: Introducing MROVI Tires and the New Didgori Trail Tread
- AI, Fintech, and Cybersecurity Divisions Ignite High-Margin Growth: IQSTEL, Inc. (N A S D A Q: IQST)
- Liquidity Aggregation: US-Registered JHKXWL Integrates AI Analytics for Brazilian and Global Institutional Traders
- Q4 2025 Outlook: JGCMGS Unveils High-Frequency Infrastructure for Italian and Global Markets
Dr. Gelblum observes, "that in this day and age of disease-modifying therapy and instantaneous telecommunications, it is unacceptable for medically necessary neurological care and treatment to be delayed."
He looks forward to welcoming Alzheimer patients from all over to his Aventura, Florida clinic.
About Jeffrey Gelblum, MD, FAAN
Dr. Jeff Gelblum is a neurologist with First Choice Neurology located in Aventura, Florida. He is considered a global thought leader in the neurologic treatment of Alzheimer's, dementia, seizure disorders, Parkinson's, diabetic and peripheral nerve disorder, Familial Amyloid Polyneuropathy, Covid Long-Hauler, trauma, and chronic pain, and has hosted educational symposia in the U.S. and overseas. To learn more about Dr. Gelblum, visit https://www.fcneurology.net/business-directory/788/jeffrey-gelblum-md/
Source: First Choice Neurology
Filed Under: Health
0 Comments
Latest on The PennZone
- Cyntexa Announces Updates to ChargeOn on Salesforce AppExchange
- Althea Gibson Honored as Final Release in U.S. Mint's American Women Quarters Program
- ToneWell Launches AI Wellness Platform with 30-Second Voice-Based Performance Readiness Scan™
- Lokal Media House Achieves Yelp Platinum Partner Status
- World's First AI-Native Industrial Facility is Under Construction by Carbon AMS with rhobot.ai
- VIP Vacations Wins Diamon Status with AIC Hotel Group
- $57 Billion U.S. Marine Industry Presents Major Growth Opportunity for Newly Public Off The Hook Yacht Sales, Inc. (N Y S E: OTH)
- Deimler Chiropractic Announces Expansion
- Dr. Alexander Eastman Returns to Suburban Hospital to Deliver Keynote on Crisis Leadership
- Scoop Social Co.'s Mobile Dessert Truck Business Offer A Lifestyle Of Flavor, Fun, and Freedom
- Own 327 Acres of American Prime Real Estate with 2 Miles Waterfront Worth In Millions for Just $7 — Worldwide Raffle Launched
- Lakefront Acreage in Longwood's Ravensbrook Community Hits the Market
- Monika Balayan Elected Fellow of the Royal Society of Arts (FRSA)
- Best Companies Group Launches Best Companies to Work for in New York Program
- We're Winning: Historic Plunge in Overdose Deaths Marks Stunning Reversal in America's Drug Crisis
- Lineus Medical Receives Patent for SafeBreak® Vascular Generation 2
- IDI Consulting Spreads Holiday Cheer to Families in Need with 11th Annual Toys for Tots Drive
- Escajeda Masonry & Concrete Among Pittsburgh's Fastest-Growing Companies
- New 2025–2026 Energy Rebates: Squeaks Services Explains How to Qualify
- CCHR's New Documentary Prescription for Violence Highlights Overlooked Safety Warnings